Register Now

Overview

This session covers the diagnosis and management of Alzheimer's disease and other common dementias, including Lewy body dementia and LATE. Learners will review NIA-AA criteria, when to order biomarkers including new plasma markers, emerging disease-modifying therapies lecanemab and donanemab, and practical approaches to driving, agitation, diet, and exercise.

Click here to answer audience response questions, access downloadable slides, and ask questions to the presenter.

The session "Memory Loss, Alzheimer's Disease, & Dementia - Update 2026" (1 hour) is designed to satisfy state licensure requirements on Dementia, Alzheimer's Disease, and Geriatrics in CT (NP), in MA (MD/DO), and in RI (MD/DO, NP).

Learning Objectives

  • Apply the NIA-AA Criteria to diagnosis Alzheimer’s disease dementia (AD) and mild cognitive impairment (MCI) due to AD
  • Explain the role of biomarkers, including new plasma markers, in the diagnosis of AD and other common dementias, including dementia with Lewy bodies
  • Discuss LATE (Limbic-predominant, Age-related, TDP-43 Encephalopathy)
  • Describe the use of lecanemab (Leqembi) and donanemab (Kisunla) in the management of AD
  • Develop strategies to manage agitation and driving safety in patients with dementia, and discuss the data on diet and exercise for memory